Intravenous Delivery Of A Multi-Mechanistic Cancer-Targeted

We have collected information about Intravenous Delivery Of A Multi-Mechanistic Cancer-Targeted for you. Follow the links to find out details on Intravenous Delivery Of A Multi-Mechanistic Cancer-Targeted.


Intravenous delivery of a multi-mechanistic cancer ...

    https://www.nature.com/articles/nature10358
    Aug 31, 2011 · Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Caroline J. Breitbach 1,Author: Caroline J. Breitbach, James Burke, Derek Jonker, Derek Jonker, Joe Stephenson, Andrew R. Haas, Laur...

Intravenous delivery of a multi-mechanistic cancer ...

    https://www.ncbi.nlm.nih.gov/pubmed/21886163
    Aug 31, 2011 · The efficacy and safety of biological molecules in cancer therapy, such as peptides and small interfering RNAs (siRNAs), could be markedly increased if high concentrations could be achieved and amplified selectively in tumour tissues versus normal tissues after intravenous administration. This has not been achievable so far in humans.Author: Caroline J. Breitbach, James Burke, Derek Jonker, Derek Jonker, Joe Stephenson, Andrew R. Haas, Laur...

Intravenous delivery of a multi-mechanistic cancer ...

    https://www.researchgate.net/profile/Jorge_Nieva/publication/51610875_Intravenous_delivery_of_a_multi-mechanistic_cancer-targeted_oncolytic_poxvirus_in_humans/links/53d90e1b0cf2e38c6331e268.pdf
    Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans Caroline J. Breitbach 1 , James Burke 2 {, Derek Jonker 3,4 , Joe Stephenson 5 , Andrew R. Haas 6 , Laura Q ...Author: Caroline J. Breitbach, James Burke, Derek Jonker, Derek Jonker, Joe Stephenson, Andrew R. Haas, Laur...

Intravenous delivery of a multi-mechanistic cancer ...

    http://adsabs.harvard.edu/abs/2011Natur.477...99B
    The efficacy and safety of biological molecules in cancer therapy, such as peptides and small interfering RNAs (siRNAs), could be markedly increased if high concentrations could be achieved and amplified selectively in tumour tissues versus normal tissues after intravenous administration. This has not been achievable so far in humans.

(PDF) Intravenous delivery of a multi-mechanistic cancer ...

    https://www.researchgate.net/publication/51610875_Intravenous_delivery_of_a_multi-mechanistic_cancer-targeted_oncolytic_poxvirus_in_humans
    Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans Article (PDF Available) in Nature 477(7362):99-102 · September 2011 with 609 Reads How we measure 'reads'

(PDF) Intravenous delivery of a multi-mechanistic cancer ...

    https://www.academia.edu/13768197/Intravenous_delivery_of_a_multi-mechanistic_cancer-targeted_oncolytic_poxvirus_in_humans
    The efficacy and safety of biological molecules in cancer therapy, such as peptides and small interfering RNAs (siRNAs), could be markedly increased if high concentrations could be achieved and amplified selectively in tumour tissues versus normal

Intravenous delivery of a multi-mechanistic cancer ...

    https://www.xconomy.com/wordpress/wp-content/images/2011/08/9-1-11-Nature-paper-JX594-intravenous.pdf
    Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic ... delivery and replication were demonstrated in a patient with baseline antibodies to JX-594/ vaccinia (Supplementary Fig. 1

Intravenous delivery of a multi-mechanistic ... - DeepDyve

    https://www.deepdyve.com/lp/nature-publishing-group-npg/intravenous-delivery-of-a-multi-mechanistic-cancer-targeted-oncolytic-XIzTVf48uu
    Aug 31, 2011 · Read "Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans, Nature" on DeepDyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips.

Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594 ...

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4817877/
    Aug 04, 2015 · This was the first clinical trial to use repeated doses of Pexa-Vec (pexastimogene devacirepvec; JX-594), or any other vaccinia or poxvirus, by intravenous infusion to treat patients with refractory, metastatic colorectal cancer. A biweekly schedule was chosen for the following reasons.Author: Se Hoon Park, Caroline J Breitbach, Jeeyun Lee, Joon Oh Park, Ho Yeong Lim, Won Ki Kang, Anne Moon, ...

Phase 1b Trial of Biweekly Intravenous ... - Molecular Therapy

    https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(16)30280-5
    Sep 01, 2015 · Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.Author: Se Hoon Park, Caroline J Breitbach, Jeeyun Lee, Joon Oh Park, Ho Yeong Lim, Won Ki Kang, Anne Moon, ...

Searching for Intravenous Delivery Of A Multi-Mechanistic Cancer-Targeted?

You can just click the links above. The data is collected for you.

Related Delivery Info